High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.
High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.
复制标题
通过早期大剂量化疗和干细胞支持治疗婴儿急性白血病的高存活率。
DOI：
10.1200/jco.2000.18.18.3256
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
M. A. Díaz
中科院分区：
文献类型：
--
作者：
Fernando Marco;E. Bureo;J. Ortega;I. Badell;A. Verdaguer;Ana Martínez;Arturo Muñoz;Luis Madero;T. Olivé;J. Cubells;V. Castel;Ana Sastre;M. Maldonado;M. A. Díaz
目的
婴儿急性白血病用常规化疗治疗预后差。目前尚不清楚干细胞移植（SCT）是否可以改善这些患者的预后。在本研究中，我们回顾了我们的经验与SCT在婴儿急性白血病澄清这一问题。
患者和方法
我们报告了26例因急性白血病接受SCT的婴儿的结果。急性髓系白血病15例，急性淋巴细胞白血病10例。1例患者患有双系白血病。22例患者首次达到完全缓解（CR1），3例达到第二次CR，1例复发。8例患者接受同种异体SCT，18例接受自体SCT。
结果
中位随访67个月，5年总生存率和无病生存率（DFS）分别为64%（SE = 9%）和63%（SE = 10%）。自体移植和同种异体SCT提供了相似的结果。没有任何移植相关的死亡，所有死亡均由SCT后前6个月内的复发引起。在多变量分析中，与更好的DFS相关的单因素是CR1和SCT之间的间隔小于4个月（P：<.025）。
结论
SCT是治疗婴儿急性白血病的有效选择，它可以克服常规化疗的高复发风险，显示出非常低的毒性。本研究表明，SCT应在疾病的早期阶段在CR1中进行。
PURPOSE
Infants with acute leukemia have a poor prognosis when treated with conventional chemotherapy. It is still unknown if stem-cell transplantation (SCT) can improve the outcome of these patients. In the present study, we review our experience with SCT in infant acute leukemia to clarify this issue.
PATIENTS AND METHODS
We report the results of 26 infants who were submitted to a SCT for acute leukemia. There were 15 cases of acute myeloid leukemia and 10 cases of acute lymphoid leukemia. One patient had a bilineal leukemia. Twenty-two patients were in their first complete response (CR1), three were in their second CR, and one was in relapse. Eight patients were submitted to allogeneic SCT, and 18 underwent autologous SCT.
RESULTS
With a median follow-up of 67 months, the 5-year overall survival and disease-free survival (DFS) are 64% (SE = 9%) and 63% (SE = 10%), respectively. Autologous and allogeneic SCT offered similar outcome. There was not any transplant-related mortality, and all deaths were caused by relapse in the first 6 months after SCT. In multivariate analysis, the single factor associated with better DFS was an interval between CR1 and SCT of less than 4 months (P: <.025).
CONCLUSION
SCT is a valid option in the treatment of infant acute leukemia, and it may overcome the high risk of relapse with conventional chemotherapy showing very reduced toxicity. This study suggests that SCT should be performed in CR1 in the early phase of the disease.
染色体 11q23 上的分子重排在婴儿急性淋巴细胞白血病中占主导地位，并与特定的生物学变量和不良预后相关。
影响因子：
20.3
作者：
Chen,CS;Sorensen,PH;Domer,PH;Reaman,GH;Korsmeyer,SJ;Heerema,NA;Hammond,GD;Kersey,JH
通讯作者：
Kersey,JH
婴儿急性淋巴细胞白血病中 HRX 重排的频率和预后意义：一项小儿肿瘤小组研究。
影响因子：
20.3
作者：
Rubnitz,JE;Link,MP;Shuster,JJ;Carroll,AJ;Hakami,N;Frankel,LS;Pullen,DJ;Cleary,ML
通讯作者：
Cleary,ML
婴儿急性非淋巴细胞白血病：临床表现和结果。
DOI：
10.1200/jco.1988.6.6.1008
发表时间：
1988
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Pui,CH;Kalwinsky,DK;Schell,MJ;Mason,CA;MirroJr,J;Dahl,GV
通讯作者：
Dahl,GV